Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001
Study Details
Study Description
Brief Summary
This will be a double-blind, placebo-controlled study with a 4-way crossover design with subjects administered study drug (JMI-001), placebo, fexofenadine alone and naproxen alone on different study days, in conjunction with a quantity of alcohol estimated to be sufficient to produce a hangover the next day. The primary objective of the study is the evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of two different doses of JMI-001 administered in conjunction with alcohol to healthy adult subjects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This will be a double-blind, placebo-controlled study with a 4-way crossover design with subjects administered study drug (JMI-001), placebo, fexofenadine alone and naproxen alone on different study days, in conjunction with a quantity of alcohol estimated to be sufficient to produce a hangover the next day. The primary objective of the study is the evaluate the pharmacokinetics and pharmacodynamics of two different doses of JMI-001 administered in conjunction with alcohol to healthy adult subjects. The secondary objective of this study is to compare the PK characteristics of fexofenadine administered as JMI-001 with administration of fexofenadine alone, and the PK characteristics of naproxen administered as JMI-001 with administration of naproxen alone. To compare overall hangover severity after administering JMI-001 with overall hangover severity after administration of fexofenadine alone or naproxen alone. To analyze possible quantitative differences in symptom profiles by treatment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: JMI-001 JMI-001 is a combination product of naproxen 220mg and fexofenadine 60mg (Dose Level one) then a combination product of naproxen 440mg and fexofenadine 120mg (Dose Level Two). |
Drug: JMI-001
JMI-001, a combination product of naproxen and fexofenadine
|
| Active Comparator: Naproxen Naproxen 220mg or 440mg |
Drug: Naproxen
Naproxen sodium 220mg
Drug: placebo
placebo comparator
|
| Active Comparator: Fexofenadine fexofenadine 60mg or 120mg |
Drug: Fexofenadine
Fexofenadine 60mg
Drug: placebo
placebo comparator
|
| Placebo Comparator: Placebo
|
Drug: placebo
placebo comparator
|
Outcome Measures
Primary Outcome Measures
- Maximum Plasma Concentration (Cmax) [24 hours]
Maximum Plasma Concentration of each drug measured in ng/mL
- Time to Maximum Plasma Concentration (Tmax) [24 hours]
Time to achieve the (Cmax) for each drug measured in hours
- Area Under the Curve (AUC) [24 hours]
Area Under the Curve for each drug measured in h*ng/mL
- Elimination half-life [24 hours]
Elimination half-life measured in hours
Secondary Outcome Measures
- Hangover Severity Score [24 hours]
Single item Hangover Score subjectively measured by the subject from 0=no symptoms to 10=worst symptoms
- Multiple Symptom Hangover Severity Score [24 hours]
A composite score derived from a spectrum of hangover symptoms (23-items) with each symptom subjectively measured by the subject from 0=no symptom to 10=worst symptom
Eligibility Criteria
Criteria
Inclusion Criteria:
- Healthy, non-smoking men or women between 21 and 65 years inclusive; 2. Good general health as determined by a thorough medical history and physical examination including vital signs; 3. Subject is a self-reported moderate drinker of alcohol, typically consuming 2 to 7 units of alcohol. Moderate drinking can be approximated with a BAC of 0.04 - 0.11%. The 0.04% - 0.11% BAC correlates approximately with a 120-160 pound female drinking 2 to 5 drinks in 2 to 3 hours, respectively, and a 160-200 pound male drinking 3 to 7 drinks in 2 to 3 hours, respectively; 4. Subject has prequalified as likely hangover-sensitive based on pre-study questionnaire; 5. Body mass index between 19 and 32 kg/m2, inclusive ; 6. Report a regular, habitual bedtime between 21:30 and 24:00; 7. Females of childbearing potential must have a negative urine pregnancy test at screening and upon admission for each treatment visit and be using an acceptable method of contraception (see Section 8.5); 8. Subject is capable of understanding the requirements of the study and to give written informed consent; 9. Subject is able to follow study instructions and is willing to complete all study visits and procedures.
Exclusion Criteria:
- Acute illness within 14 days prior to screening visit; 2. Allergic reaction or upper respiratory tract infection within 7 days of screening visit; 3. Vaccination administration within 7 days of screening visit; 4. Clinically significant, unstable medical illness; 5. Evidence or history of clinically significant autoimmune, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic or neurological disease; 6. History of cancer or diabetes; 7. Subject has a previous or current Substance-Related Disorder as defined by DSM 5; 8. A score of 8 or greater on the AUDIT scale; 9. Self-report of recent (within one month) or current use of smoked or chewed tobacco products, or use of nicotine (e.g., nicotine gum or patch); 10. Positive alcohol Breathalyzer test at check-in for any treatment visit; 11. Positive urine drug screen at screening or at check-in for any treatment visit; 12. A seated blood pressure > 140/90 mm/Hg at screening; 13. Heart rate > 100 beats per minute at screening; 14. Subjects who are unwilling to forgo caffeine consumption with or following dinner on each treatment night or who are unwilling to comply with study restrictions for prohibited medications/ foods throughout study participation;
- Clinically significant psychiatric illness, including chronic psychiatric illness or the history or presence of any Axis I condition; 16. Any clinically significant abnormal finding on physical examination or vital signs; 17. Subject has previously experienced an allergic reaction or adverse event associated with aspirin, NSAIDs, or antihistamine usage;
- Subject requires the use of any prescription or over-the-counter (OTC) oral pain medication(s) on study treatment days; 19. Women who are breastfeeding; 20. Any medical condition or any condition or situation that in the investigator's opinion may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study; 21. Concurrent participation in an investigational drug or device study, or use of any investigational drug within 30 days prior to screening.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sen-Jam Pharmaceutical
Investigators
- Principal Investigator: Magdy L Shenouda, MD, Clinilabs, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SJP-1-01